quinoxalines has been researched along with Cancer of the Urinary Tract in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 5 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hanna, KS | 1 |
| Chang, SS | 1 |
| de Almeida Carvalho, LM; de Oliveira Sapori Avelar, S; Gill, J; Haslam, A; Prasad, V | 1 |
| Grülllich, C | 1 |
| Burgess, M; English, A; Hartmann, A; Major, C; Sweeney, M; Wang, S | 1 |
| Ertl, IE; Ilijazi, D; Loriot, Y; Mostafaei, H; Shariat, SF | 1 |
| Comet, A; Denis, D; Ramtohul, P | 1 |
| Markham, A | 1 |
| Avadhani, A; Burgess, E; De Porre, P; Duran, I; Fleming, M; Garcia-Donas, J; Huddart, R; Joshi, M; Loriot, Y; Mellado, B; Necchi, A; O'Hagan, A; Park, SH; Rezazadeh, A; Santiago-Walker, A; Siefker-Radtke, AO; Stuyckens, K; Tagawa, ST; Varlamov, S; Zakharia, Y; Zhong, B | 1 |
| Burki, TK | 1 |
3 review(s) available for quinoxalines and Cancer of the Urinary Tract
| Article | Year |
|---|---|
Erdafitinib to treat urothelial carcinoma.
Topics: Humans; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor; Urologic Neoplasms; Urothelium | 2019 |
[High response rates for erdafitinib in patients with FGFR-mutated urothelial carcinoma following failure of platinum-based chemotherapy].
Topics: Carcinoma, Transitional Cell; Humans; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Treatment Outcome; Urologic Neoplasms; Urothelium | 2020 |
Fibroblast growth factor receptors across urothelial carcinoma landscape.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Humans; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 3; Receptors, Fibroblast Growth Factor; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms | 2020 |
2 trial(s) available for quinoxalines and Cancer of the Urinary Tract
| Article | Year |
|---|---|
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Humans; Kaplan-Meier Estimate; Middle Aged; Mutation; Neoplasm Metastasis; Progression-Free Survival; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor; Treatment Outcome; Urologic Neoplasms; Urothelium | 2019 |
Erdafitinib for advanced urothelial carcinoma.
Topics: Carcinoma, Transitional Cell; Drug-Related Side Effects and Adverse Reactions; Humans; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Urologic Neoplasms; Urothelium | 2019 |
5 other study(ies) available for quinoxalines and Cancer of the Urinary Tract
| Article | Year |
|---|---|
Re: Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
Topics: Carcinoma, Transitional Cell; Humans; Pyrazoles; Quinoxalines; Urologic Neoplasms | 2020 |
Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib.
Topics: Antineoplastic Agents; Genetic Variation; Humans; Neoplasms; Off-Label Use; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Urologic Neoplasms | 2019 |
Identifying fibroblast growth factor receptor genetic alterations using RNA-based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment.
Topics: Aged; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Pyrazoles; Quinoxalines; Real-Time Polymerase Chain Reaction; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Urologic Neoplasms | 2020 |
Pseudovitelliform Maculopathy Associated with FGFR Inhibitor Therapy.
Topics: Aged, 80 and over; Fluorescein Angiography; Fundus Oculi; Humans; Macula Lutea; Macular Degeneration; Male; Pyrazoles; Quinoxalines; Tomography, Optical Coherence; Urologic Neoplasms | 2021 |
Erdafitinib: First Global Approval.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Drug Approval; Humans; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Treatment Outcome; United States; United States Food and Drug Administration; Urologic Neoplasms | 2019 |